Ddx42p is a recently characterized mammalian DEAD box protein with unknown cellular function. We found that in human cells Ddx42p physically interacts with ASPP2, a major apoptosis inducer known to enhance p53 transactivation of proapoptotic genes. The proteins interact via a domain within the carboxy-terminal part of Ddx42p and a mid-amino-terminal sequence as well as the ankyrin-SH3 region of ASPP2. Overexpression of Ddx42p interferes with apoptosis induction by ASPP2, whereas Ddx42p knockdown reduces the survival rate of cultured human cells. In addition, ASPP2 is found in cytoplasm and nucleus at low Ddx42p level, and predominantly in cytoplasm at high concentration of Ddx42p, respectively. Our results show that Ddx42p is capable of modulating ASPP2 function.
Introduction
The apoptotic but not the cell-cycle arrest function of p53 family proteins is activated by ASPP1 and 2 and inhibited by iASPP, respectively (Trigiante and Lu, 2006 and citations therein). All three proteins share a prolinerich region, ankyrin repeats (ank) and an SH3 (src homology region 3) domain in their carboxy (C-) termini. The ank-SH3 region binds to ASPP2 interaction partners, which include the p53 family (Bergamaschi et al., 2004) and other proteins related to apoptosis/proliferation such as Bcl-2 (Naumovski and Cleary, 1996) , nuclear factor-kB subunit 3 (Yang et al., 1999) and amyloid b-precursor protein-binding protein 1 (APP-BP1; Chen et al., 2003) . Cellular ASPP2 status is tightly controlled at transcriptional (Lopez et al., 2000; Stanelle et al., 2002) and protein levels (Zhu et al., 2005) , and the proline-rich region of ASPP2 competes with other binding partners . In some carcinomas, mostly those expressing wild-type p53, the ASPP2 gene is silenced by hypermethylation (Liu et al., 2005) , which could be linked to tumour progression.
Some DEAD box (Ddx) proteins, such as Ddx5 (p68; Bates et al., 2005) or Ddx3 (Chao et al., 2006) , also act as tumour suppressors. Ddx proteins belong to helicase superfamily II (Gorbalenya and Koonin, 1993) and at least some of them catalyse RNA unwinding. Acting as RNA chaperones, they seem to support virtually all RNA-related processes (Linder, 2006) . Ddx5 and its close relative Ddx17 (isoforms p72 and p82; UhlmannSchiffler et al., 2002) are truly outstanding with respect to the diversity of their physiological functions (Ishizuka et al., 2002; Ho¨ck et al., 2007; Jalal et al., 2007) , including those that seem not to require their RNAspecific activity (reviewed in Fuller-Pace, 2006) .
Ddx42p is related to Ddx5 and Ddx17 closer than any other known DEAD protein, yet differs in biochemical features (Uhlmann-Schiffler et al., 2006) . It was found in the 17S U2 snRNP splicing complex . A pathogenesis-relevant interaction of Ddx42p with Japanese Encephalitis Virus NS4A protein (Lin et al., 2008a) is reminiscent of Ddx5 interacting with Hepatitis C virus NS5B (Goh et al., 2004) in viral replication. Yet, no specific cellular function or interaction partners of Ddx42p are known.
Here, we report on physical interaction of Ddx42p and ASPP2, which interferes with the apoptosisstimulating effect of ASPP2.
Results

Ddx42p physically interacts with ASPP2
The individual amino-(N-) and C-terminal parts of most Ddx proteins are prone to provide interfaces for interactions with various partners in specific processes. We used a yeast two-hybrid approach with an Nterminal Ddx42p deletion mutant (Ddx42p(685-938)) as bait to identify interacting polypeptides expressed from a HeLa cDNA library (Figure 1) . A positive clone encoded full-length ASPP2, a known p53 binding protein (NM_001031685). In a subsequent pull-down assay, purified , expressed in Escherichia coli, bound to ASPP2 from HeLa cell extracts (Figure 2a) . The unique C-terminus of Ddx42p is thus sufficient for this interaction, whereas its Nterminal and helicase consensus sequences (Linder, 2006) are dispensable.
Binding of Ddx42p to ASPP2 was further confirmed by coimmunoprecipitation (co-IP) of native proteins from extracts of various mammalian cell lines (Figure 2b) , including H1299 cells (data not shown). Notably, the latter ones do not express p53, which is thus not required for complex formation. RNA, by supplementing the extraction buffer with RNase A, was also excluded as contributing to complex formation (data not shown). ASPP2-Ddx42p interaction was verified using respective overexpressed proteins in co-IP experiments (Figure 2c ). Ddx42p(1-833), which lacks 105 C-terminal amino acids (aa), still bound to ASPP2 (data not shown), whereas Ddx42p(1-737) failed to coprecipitate with ASPP2 ( Figure 2c ). The domain sufficient for ASPP2 binding thus resides within aa 738-833 of Ddx42p.
To specify ASPP2 interacting domains, ASPP2 deletion mutants (Figure 3a ) and Ddx42p were overexpressed in COS cells and subjected to co-IP (Figures 2c and 3b) . These experiments show that both a mid-N-terminal (aa 415-489) and the C-terminal part (aa 950-1134) of ASPP2 participate in interaction with Ddx42p.
The N-terminal Ddx42p binding site (aa 415-489) resides within a region of ASPP2 that is subject to ubiquitination (aa 401-847; Zhu et al., 2005) . However, ubiquitination does not interfere with complex formation as shown by similar ubiquitination states of total ASPP2 and the Ddx42p-complexed ASPP2 fraction, respectively (Figure 3c ).
Cellular survival rate depends on Ddx42p
We analysed cellular consequences of the Ddx42p-ASPP2 interaction. First, the effects of overexpression of Ddx42p, ASPP2 or both, respectively, were examined in several cell lines by a colony formation assay ( Figure 4a ). When compared with the respective mocktransfected controls, exogenic Ddx42p expression moderately increased the cellular survival rates, whereas ASPP2 overexpression reduced it to a similar extent. The latter result confirms the reported main cellular effect of ASPP2, induction of apoptosis (Yang et al., 1999; Lopez et al., 2000) . Importantly, coexpression of Ddx42p along with ASPP2 attenuated the effect of ASPP2 on clonogenic survival. As seen from experiments with HCT116 p53À/À cells, p53 was not essential in this process (Figure 4a ).
We note that overexpression of Ddx42p ( Figure 4b , lane 2) or its knockdown (lane 3) did not affect the level of endogenous ASPP2. Vice versa, altered ASPP2 levels do not influence endogenous Ddx42p expression ( Figure 4b , lanes 4-5; data not shown). Accordingly, the level of endogenous Ddx42p remained unaffected under physiological stress conditions, such as DNA damage by ultraviolet (UV) irradiation, whereas an almost threefold induction of ASPP2 (Figure 4b , lanes 6-9; see also Lopez et al., 2000) was observed under these conditions. We further checked whether Ddx42p is also capable of rescuing cells stressed by UV-C treatment and studied clonogenic survival and apoptotic rates (Annexin V staining) of irradiated cells in which Ddx42p was either overexpressed or knocked down ( Figure 5 ). Indeed, survival of cells was enhanced at increased Ddx42p levels independently of the presence (MCF-7 and HCT116 p53 þ / þ cells) or absence (HCT116 p53À/À and H1299 cells) of p53, and efficiently decreased at low Ddx42p concentration (Figure 5a , upper left-hand panel). However, after ASPP2 knockdown, the number of viable (non-apoptotic, Annexin V-negative) cells did not increase on simultaneous overexpression of Ddx42p (Figure 5a , upper right-hand panel). Indicating apoptosis, UV-irradiated control and Ddx42p knockdown cells lost their nuclear integrity (condensed morphology; Earnshaw, 1995; Lopez et al., 2000) , whereas nuclei of Ddx42p-overexpressing cells appeared normal in immunofluorescence studies ( Figure 5b ). . Yeast was grown on double-dropout (selecting for expression of the respective Gal4-DNA-BD and Gal4-AD constructs) and triple-dropout media (selecting for interaction of the respective proteins expressed from these constructs). A positive clone (A), growing on respective selection media, encoded full-length ASPP2 (NM_001031685). Negative (B, C, D) and positive (E) controls verified that this interaction was specific.
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These results confirm an antiapoptotic effect of Ddx42p that was confirmed by Annexin V staining experiments in which ASPP2 was overexpressed along with Ddx42p in HCT116 cells (p53À/À cells shown in Figure 5a , lower panel; p53 þ / þ cells, data not shown). In otherwise unstressed cells, ASPP2 overexpression causes little reduction in cell viability, which corresponds to former results (Zhu et al., 2005) . After varying doses of UV stress, the fraction of viable cells is decreased on ASPP2 overexpression, and simultaneous overexpression of mutant Ddx42p(1-737) did not rescue cells. Expression of full-length Ddx42p along with ASPP2, in contrast, restored cell viability to control values at all UV doses used. Physical interaction of ASPP2 and Ddx42p is therefore required, and p53 not essential, for the observed effect.
Ddx42p is capable of relocalizing ASPP2
Ddx42p is a nuclear protein (Uhlmann-Schiffler et al., 2006) with trace amounts detected in the cytoplasm, and its overexpression does not change this distribution in COS cells (Figure 6a ). Endogenous ASPP2, in contrast, was found in the cytoplasm and nucleus, yet was excluded from the nucleus on overexpression of Ddx42p (Figure 6a ). In contrast, the non-binding mutant Ddx42p(1-737) did not sequester ASPP2 to the cytoplasm (Figure 6a) . ASPP2 redistribution by Ddx42p was confirmed by exogenously expressed (myc-tagged) ASPP2 (Figure 6b ) and ASPP2(1-620) (data not shown), respectively. Overexpression of these proteins caused nuclear disintegration and irregular nuclear morphology (Figure 6b ) typical of apoptosis (Earnshaw, 1995; Yang et al., 1999) and consistent with the cellular function of ASPP2. Coimmunoprecipitations (Co-IPs) were performed with Ddx42p-specific antibodies a-D42C (lane 3). Preimmune serum (lane 2) was used as a control. Western blots were probed with a-ASPP2 and a-D42C, respectively. (c) Ddx42p is coprecipitated with myc-tagged ASPP2 proteins. Full-length Ddx42p was overexpressed in COS cells along with ASPP2 (lane 1) and ASPP2(1-620) (lane 4), respectively. Co-IPs with full-length ASPP2 (lane 3) and ASPP2(1-620) (lane 6), respectively, were carried out with a-myc antibody. Western blots were probed with a-D42C and a-myc, respectively. Ddx42p(1-737), lacking the C-terminal 200 amino acids, was overexpressed and subjected to co-IP as described and detected with Strep antibody (lanes 7 and 9). Co-IPs with cells cotransfected with empty pCMV-Myc vector and either pCddx42 or pCddx42(1-737) (lanes 2, 5 and 8, respectively) served as a control. (b and c) 'Input' is 10% of the respective cell extract used for co-IP.
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H Uhlmann-Schiffler et al ASPP2(1-620)-overexpressing cells were also affected (data not shown), and thus the N-terminus seems to be sufficient for full proapoptotic activity (see also Samuels-Lev et al., 2001) . Simultaneous overexpression of Ddx42p and ASPP2, on the other hand, resulted in translocation of ASPP2 to the cytoplasm with no apoptotic nuclear morphology detectable (Figure 6b ).
Cellular levels of Ddx42p differ from cell line to cell line (Uhlmann-Schiffler et al., 2006) , and HEK293 cells show a higher content than, for example, MCF-7 or COS cells (Figure 6d ). Whereas in the latter two, ASPP2 was found in the nucleus and cytoplasm (Figure 6d ), we confirmed that it was mainly excluded from the nucleus in HEK293 cells (Figures 6a and d ; Kobayashi et al., 2005) irrespective of its nuclear import signal (aa 964-1029; Sachdev et al., 1998; Yang et al., 1999) , and the same holds true for H1299 cells (Figure 6c ). In contrast, Ddx42p localization was similar in all four cell types (nuclear with trace amounts in the cytoplasm). ASPP2 localization may thus depend on the relative levels of ASPP2 and Ddx42p in a given cell. Accordantly, transient knockdown of Ddx42p in HEK293 or H1299 cells led to nuclear relocalization of endogenous ASPP2 (Figure 6c ), whereas in MCF-7 or COS cells, Ddx42p knockdown had no effect on cellular ASPP2 distribution (data not shown).
Discussion
ASPP2, a haplo-insufficient tumour suppressor (Vives et al., 2006) , is known to form complexes with a variety of proteins. Its newly discovered interaction partner, Ddx42p, binds to ASPP2 via a mid-C-terminal domain (lanes 2-7) . Lower molecular weight bands (particularly in lanes 4 and 5) most likely represent proteolytic degradation products. Cells for co-IP control were transfected with pCddx42 and empty pCMV-Myc vector (lane 1). Co-IP was done with a-myc and western blots probed with a-D42C and a-myc, respectively. (c) ASPP2 ubiquitination does not interfere with Ddx42p binding. Identical amounts of an MCF-7 extract were subjected to precipitation assays with either a-ASPP2 (lanes 1 and 3) or a-D42C (lanes 2 and 4). Respective precipitates were blotted with a-ASPP2 (lanes 1 and 2) as a measure for total ASPP2 precipitated, and with a-ubiquitin (lanes 3 and 4) to detect the fraction of ubiquitinated ASPP2 in both samples.
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H Uhlmann-Schiffler et al (aa 738-833), which is unique to Ddx42p within the large Ddx family (Uhlmann-Schiffler et al., 2006). Ddx42p and ASPP2 interact independently of p53 through a mid-N-terminal (aa 415-489) and a C-terminal region of ASPP2, the latter including the ank-SH3 region (aa 950-1134). Thus, not involved in binding are (1) the b-grasp fold (aa 7-89 of ASPP2) belonging to the interaction-prone ubiquitin-like superfamily (Tidow et al., 2007) and (2) the predicted a-helical domain of ASPP2 (aa 130-329; Naumovski and Cleary, 1996) , which is somewhat surprising as critical proteinprotein contacts are mediated through a-helices, for example, in the p53*MDM2 (Kussie et al., 1996) or the Myc*Max complex (Bagnasco et al., 2007) . However, our results (Figures 3a and b) imply that Ddx42p could also bind to Bbp, a shorter splice variant of ASPP2 (aa 129-1134; see below). In addition, the interaction of Ddx42p with ASPP2 is reminiscent of that of APP-BP1. This protein, like Ddx42p, also contacts two (apparently overlapping) sites in ASPP2 and inhibits apoptosis (Chen et al., 2003) . Also, contacting the ASPP2 C-terminus is common to other ASPP2 interaction partners (see Introduction) and may therefore cause binding competition by Ddx42p. On the other hand, all three ASPP proteins share the ank-SH3 domains. Ddx42p might thus be capable of binding to ASPP1 and/or iASPP as well, thereby potentially modulating their functions, the study of which will be an interesting future task.
ASPP2 concentration inversely correlates with the UV resistance of mammalian cells (Lopez et al., 2000) , and ASPP2 stimulates apoptosis (Yang et al., 1999; Samuels-Lev et al., 2001; Bergamaschi et al., 2004) . We show that Ddx42p overrode this effect under various conditions, and Ddx42p knockdown had a proapoptotic effect (Figures 4 and 5) . Interestingly, other Ddx proteins, such as Ddx25 (Gutti et al., 2008) and rck/ p54 (Lin et al., 2008b) , also promote cell proliferation, and their knockdown induces apoptosis, by yet unknown mechanisms. Ddx42p(1-737), lacking the C-terminal domain that binds to ASPP2, did not interfere with cellular survival, and was incapable of counteracting ASPP2-induced apoptosis. This indicates that ASPP2*Ddx42p complex formation is critical for attenuation of the proapoptotic function of ASPP2 by Ddx42p.
Our results suggest that Ddx42p-bound ASPP2 has lost its apoptosis-stimulating activity, perhaps similar to the antiapoptotic effect of Bcl-2 binding to Bbp, an ASPP2 isoform (aa 129-1134; Takahashi et al., 2005) . Bcl-2, in fact, competitively inhibits p53 binding to the ank-SH3 domains of Bbp/ASPP2 (Naumovski and Cleary, 1996) , whereas Ddx42p apparently also acts in the absence of p53. However, in p53-free cells, p53 subfamily proteins p63 and p73 at least partially substitute for p53 and interact with ASPP2 (Bergamaschi et al., 2004) . Thus, it has to be checked in future experiments whether Ddx42p interferes with p53/p63/ p73 binding to ASPP2.
ASPP2 knockdown, on the other hand, did not significantly increase the survival of unstressed cells (Zhu et al., 2005) , which was confirmed in this study. On UV treatment of ASPP2 knockdown cells, Ddx42p showed no obvious protective effect. Combined with the ASPP2 and Ddx42p were also studied with respect to their intracellular localization. Interestingly, nuclear disintegration typical of apoptosis (Earnshaw, 1995;  Figure 5 Ddx42p protects cells from ASPP2-induced apoptosis after UV stress. (a) Ddx42p counteracts ASPP2-induced apoptosis. Upper left-hand panel: Clonogenic survival depends on cellular Ddx42p levels. After transfection with pCddx42 and ddx42 si RNA, respectively, indicated cell lines were analysed for colony formation either directly or after UV irradiation ( þ UV; 35 J/m 2 ). Control refers to cells transfected with empty vector and control siRNA, respectively. Upper right-hand panel: The antiapoptotic effect of Ddx42p is ASPP2-dependent. Cells were transfected with aspp2 si RNA plus empty vector (si aspp2) and aspp2 si RNA plus pCddx42 (si aspp2 þ pCddx42), respectively, UV-C-irradiated at indicated doses after 24 h, and the fraction of viable cells determined by Annexin V staining and flow cytometry. Lower panel: Cell viability after UV treatment depends on Ddx42p-ASPP2 interaction. Cells were transfected with the indicated plasmids (control, empty vector), UV treated at increasing doses and subsequently analysed by Annexin V staining and flow cytometry. Results are shown as mean values of at least three independent experiments each. (b) Microscopic analysis of MCF-7 cells. Ddx42p-overexpressing ( þ pCddx42) and -knockdown (si ddx42) cells were UV treated (35 J/m 2 ), followed by indirect immunofluorescence using a-D42C and DAPI staining. Control cells (transfected with empty vector) are also shown. 
H Uhlmann-Schiffler et al Yang et al., 1999) was detected on overexpression of ASPP2 ( Figure 6b ) as well as ASPP2(1-620), the effect of the latter possibly due to competitive release of endogenous (full-length) ASPP2 from Ddx42p complexes. At high Ddx42p levels, ASPP2 seems to be excluded from the nucleus with no apoptotic nuclear Ddx42p counteracts ASPP2 H Uhlmann-Schiffler et al morphology detectable (Figure 6 ), whereas a nonbinding Ddx42p mutant, Ddx42p(1-737), does not mediate ASPP2 delocalization. Interaction of Ddx42p with ASPP2 is thus required for this effect. Two possible mechanisms can be envisaged for this phenomenon:
(1) Ddx42p directly or indirectly mediates nuclear export of ASPP2 or (2) blocks import of ASPP2 into the nucleus. As a consequence, ASPP2, in either case, would have no access to nuclear proapoptotic transcription factors such as p53 as has been suggested for another tumour suppressor, Ddx3 (Chao et al., 2006) . At present, we cannot exclude that some of the Ddx42p*ASPP2 complexes are located in the nucleus as well. These may be transcriptionally inactive and, via binding competition, might directly block the effect of ASPP2 on transactivation of proapoptotic genes. Intriguingly, ASPP2 and/or its isoform Bbp have also been inferred to induce apoptosis through the mitochondrial death pathway , which might be exerted through inhibiting functional sites of antiapoptotic Bcl-2 by ASPP2/Bbp binding . As a fraction of Ddx42p is found in the cytoplasm, and the protein is capable of binding to respective ASPP2 deletion mutants (Figure 3) , it could also bind to and inactivate cytoplasmic ASPP2 isoforms.
Taken together, our study shows that Ddx42p binds to and counteracts ASPP2 with respect to apoptosis stimulation independently of p53. This process depends on the cellular level of Ddx42p, includes delocalization of ASPP2 and may be based on competitive binding of Ddx42p to the ank-SH3 region of ASPP2.
Materials and methods
Yeast two-hybrid screen A HeLa cDNA library was screened (Matchmaker yeast twohybrid system; Becton Dickinson GmbH, Heidelberg, Germany). DNA-BD-Ddx42p(685-938) resulted from recloning of ddx42 cDNA into pGBKT7 via NdeI/BamHI and removal of an NdeI/StuI fragment. Plasmid DNA from positive yeast clones was isolated and sequenced (Dr R Klein, Kaiserslautern, Germany). pCaspp2 was obtained by PCRcloning of ASPP2 cDNA into pCMV-Myc (Becton Dickinson) via SfiI/XhoI. pCaspp2(1-620) results from a premature stop codon. Other ASPP2 cDNA expression vectors were derived from pCaspp2 and pCaspp2(1-620). Ddx42p expression plasmid pCddx42 was described previously (Uhlmann-Schiffler et al., 2006). pCddx42(1-737), a mammalian expression vector for Strep-tagged Ddx42p(1-737), was obtained by recloning the ddx42 cDNA into pEXPR-IBA vector (IBA, Go¨ttingen, Germany) and removal of an EcoRI/BamHI fragment.
Co-IP Cells, transfected as indicated, were lysed on ice in 10 mM sodium phosphate pH 8.0, 10 mM NaCl, 0.5% NP40 (v/v), 1 mM EDTA with Complete protease inhibitor cocktail (Roche Diagnostics GmbH, Mannheim, Germany) and spun at 20 000 g for 20 min. Cell extracts were incubated with antibodies a-D42C (Uhlmann-Schiffler et al., 2006), a-c-myc clone 9E10 from Roche, a-ASPP2 clone DX54.10 (directed against aa 697-1134) from Sigma-Aldrich Biochemie GmbH (Hamburg, Germany) or non-specific IgG, respectively, bound to protein A sepharose 6MB (GE Healthcare, Mu¨nchen, Germany). The washed beads were eluted with SDS-polyacrylamide gel electrophoresis (PAGE) loading buffer and complexes analysed by SDS-PAGE and western blotting. a-Ubiquitin clone 6C1 was from Sigma, a-actin antibodies (I-19)-R from Santa Cruz Biotechnology Inc. (Heidelberg, Germany), and Strep-tag II specific monoclonal antibody from IBA, respectively. a-D42N was described previously (Uhlmann-Schiffler et al. 2006) . Quantification of protein bands in western blots was done by the Quantity One Analysis Software package (Bio-Rad Laboratories GmbH, Mu¨nchen, Germany).
Pull-down assay Ddx42p(685-938) was recloned into pRSETC via XhoI/PstI, expressed in E. coli and purified (Uhlmann-Schiffler et al., 2006) . The protein was mixed with cell extract, applied to a TALON resin (Becton Dickinson), washed, and eluted with buffer containing 150 mM imidazole. Samples were analysed by SDS-PAGE and immunoblotting.
Cellular survival and viability assays
For colony formation assays, 5 Â 10 2 , 10 3 and 5 Â 10 3 cells were plated 24 h after transfection. Where indicated, cells were UVirradiated at 254 nm, 35 J/m 2 before plating. After 10-14 days, colonies were stained in 1% (w/v) crystal violet. si ddx42 RNA was obtained by in vitro SP6 and T7 transcription of pGEMddx42 (Uhlmann-Schiffler et al., 2006) , RNA annealing, and RNase III (New England Biolabs Inc., Frankfurt am Main, Germany) digest. For ASPP2 knockdown, a validated si aspp2 RNA (Zhu et al., 2005) was obtained from Qiagen (Hilden, Germany). As a control, AllStars negative control siRNA (Qiagen) was used. For cell viability assays, cells were UV treated as indicated 24 h after transfection, harvested after another 24 h period (including cells floating in the medium), fluorescence stained using the Annexin V-Fluos Staining kit (Roche), and quantified by flow cytometry on a BD FACS Canto II (Becton Dickinson).
Immunofluorescence Cells were fixed with 3.7% (v/v) formaldehyde and permeabilized with 0.2% (v/v) Tween 20 in phosphate-buffered saline. Goat-anti-rabbit Alexa Fluor 488 and goat-anti-mouse 568, F(ab 0 ) 2 fragments H þ L (Invitrogen, Karlsruhe, Germany) were used at 3 mg/ml, and DAPI at 1 mg/ml, and fluorescence detected on an Eclipse TE-2000U fluorescence microscope (Nikon GmbH, Du¨sseldorf, Germany). Pictures were digitally taken at 200-to 400-fold magnification.
